Nyxoah files Registration Statement for Proposed Initial Public Offering in the United States

Nyxoah files Registration Statement for Proposed Initial Public Offering in the United States

Mont-Saint-Guibert, Belgium – June 10, 2021, 11:30pm CET / 5:30pm ET – Nyxoah SA (Euronext Brussels: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the “SEC”) relating to a proposed initial public offering of its ordinary shares, which are expected to be listed on the NASDAQ Global Market in the United States.  The number of ordinary shares to be offered and the price for the proposed offering have not yet been determined.

Nyxoah’s ordinary shares are currently listed on Euronext Brussels under the symbol “NYXH”. An application has been made to list the ordinary shares on the NASDAQ Global Market under the same symbol.

Piper Sandler, Stifel and Cantor are acting as joint book-running managers for the proposed offering. Degroof Petercam is acting as a manager.

A registration statement on Form F-1 has been filed with the SEC but has not yet become effective. The ordinary shares may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification or publication of an offering prospectus under the securities laws of any such state or jurisdiction.

The proposed offering of ordinary shares in the United States will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the proposed offering can be obtained from Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by e-mail at prospectus@psc.com, or by phone at (800) 747-3924; Stifel, Nicolaus & Company, Incorporated at Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720, or by email at syndprospectus@stifel.com; or Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue, 4th Floor, New York, New York 10022; email: prospectus@cantor.com.

Contacts:

Nyxoah
Fabian Suarez, Chief Financial Officer
fabian.suarez@nyxoah.com
+32 10 22 24 55

Gilmartin Group
Vivian Cervantes
vivian.cervantes@gilmartinir.com

Attachment

Layout International Partners with Sophi.io to Fully Automate Print Production

Combining Layout International’s NewsPublish and Sophi.io’s smart AI and ML engine reduces the hours long process of print laydown to just minutes

TORONTO, June 10, 2021 (GLOBE NEWSWIRE) — Sophi.io, a suite of AI-powered optimization, prediction and automation tools developed by The Globe and Mail, has partnered with Layout International, a supplier of cutting-edge enterprise technology, to transform print production. Sophi will provide the smart AI/ML technology to fully automate the end-to-end print production workflow to save publishers time and money and enable them to focus on creating high quality content.

Print laydown is typically a long and arduous process, involving multiple editors and page designers and taking hours to complete. Without the rigid constraints of a template, Layout International customers will now have the opportunity to create a print-ready paper that is indecipherable from a paper prepared by human page designers, and the entire process takes just minutes. And for Layout International’s over 200 customers, this partnership means seamless integration of Sophi into their current NewsPublish editorial workflow.

“We’re excited that working with Sophi.io enables us to offer our customers cutting edge new capabilities in the form of an end-to-end automated print solution that dramatically increases efficiencies. Our customers will be able to run and rerun their print paper in just minutes, whenever they chose, all within the NewsPublish Enterprise content management system that they already use daily,” said Jean-Michel Habis, CEO of Layout International.

The Sophi suite of tools is designed to identify an organization’s most valuable content (not the most popular content, but the content that drives conversions or retention or the metric that matters most to that organization) and place it in the most valuable places across their digital entities, or behind a paywall when the subscription revenue outweighs the predicted advertising revenue. In addition to NewsPublish powered by Sophi.io, Sophi provides site automation, a fully dynamic, real-time, personalized paywall, and analytics solutions to publishers across the world.

“Print laydown is a massive undertaking,” said Greg Doufas, Chief Technology Officer at The Globe and Mail. “We see this partnership with Layout International giving publishers the freedom to focus on content creation and the specific design elements that page designers want to spend their energy on. The best part is that NewsPublish powered by Sophi.io is getting better and smarter every day, so Layout International customers will always be on the cutting edge of technology with this solution.”

To learn more, please visit www.newspublish.org or email sales@layoutintl.com.

About Layout International
Layout International (www.layoutintl.com) meets the growing technological needs in the market by providing highly customizable enterprise solutions. They serve more than 200 clients, supplying them with cutting-edge technology to improve the way they work. They enable many organizations to digitally transform their processes, migrate and integrate to work on a single platform.

Layout International Media Contact
Ghassan Halawi
Vice President of Sales, Layout International
+961 70 855685
ghalawi@layoutintl.com

About Sophi.io
Sophi.io (https://www.sophi.io) is a suite of AI-powered optimization and prediction tools that helps content publishers make important strategic and tactical decisions. Sophi solutions range from Sophi Site Automation and Sophi for Paywalls to Sophi Analytics, a decision-support system for content publishers. Sophi is designed to improve the metrics that matter most to your business, such as subscriber retention and acquisition, engagement, recency, frequency and volume.

Sophi.io Media Contact
Jamie Rubenovitch
Head of Marketing, Sophi.io
The Globe and Mail
416-585-3355
jrubenovitch@globeandmail.com

British Doctors Union Urges Government Not to Reopen

The main doctors union in Britain is calling on the government to delay its plans to ease coronavirus lockdown restrictions as new data shows a spike in cases of the highly transmissible delta variant.

The British Medical Association said Friday a “sensible delay” would help to stop infections from rising.

Government figures on Friday showed 8,125 new COVID-19 cases, the highest daily total since February. The delta variant, originally identified in India, now accounts for 90% of all new cases in the country.

According to the COVID-19 Roadmap laid out by Prime Minister Boris Johnson’s government, all pandemic-related restrictions are scheduled to be lifted June 21, one week from Monday.

However, in an interview Friday, England’s COVID-19 vaccines minister, Nadhim Zahawi, told Times Radio the nation must be very careful about the opening, given the dominance of the delta variant.

Zahawi said the government should examine the data from this coming weekend very carefully and share it with the nation, and then decide about reopening.

Johnson is expected to announce on Monday whether the planned lifting of restrictions will go ahead.

The Sun newspaper reported Friday that Johnson will hold off on easing the lockdown restrictions.

Meanwhile, Chicago became the largest U.S. city to fully reopen Friday. During a news conference formally announcing the reopening, Mayor Lori Lightfoot told reporters that for more than a year, Chicago residents have endured so much, but they did their part every step of the way.

“You masked up, you got vaxxed up, and now it’s time for you to get up, get out of the house this summer and fully and safely enjoy the events of the best city on the planet, our beloved city of Chicago,” Lightfoot said.

Earlier Friday, leaders from the G-7 nations announced they will donate a billion COVID-19 vaccine doses to low- and medium-income nations. The U.S. will donate 500 million shots, while Britain will donate 100 million doses.

In the United States, the Centers for Disease Control and Prevention said Friday that 64% of Americans 18 and older had had at least one dose of a coronavirus vaccine.

The Associated Press reported Friday that because of slowing demand for vaccinations, some states have stopped new orders for vaccine doses and others have sent millions of doses back to the federal government. States sending vaccines back to the government include Tennessee and North Carolina, even though less than half of their populations have been vaccinated.

In other developments Friday, Malaysia’s government said it would extend a two-week nationwide lockdown by another two weeks because daily infections remain high at more than 6,000.

Sri Lanka also extended its lockdown for another week as deaths from COVID-19 surpassed 2,000 on Friday.

The Johns Hopkins Coronavirus Resource Center said Friday the number of global COVID-19 infections has reached more than 175 million. The U.S. remains the location with the most cases at 33.4 million infections, but India is rapidly catching up with more than 29.3 million infections.

India’s health ministry reported more than 91,000 new COVID-19 cases Friday in the previous 24 hours. Public health officials say they suspect that India’s cases may be undercounted.

Source: Voice of America

IRS Data Leak Reveals How Little America’s Wealthiest Pay in Taxes

An unprecedented leak of the personal federal tax data of thousands of Americans has turbocharged a debate over wealth inequality in the United States and has tax reform advocates hopeful that a deeper public understanding of how the wealthy avoid taxes will lead to a restructuring of the U.S. tax code.

The data, leaked to the nonprofit journalism organization ProPublica, includes detailed information on the tax filings of thousands of the wealthiest individuals in the country and extends over more than 15 years.

This week, ProPublica used the data to give the nation its first detailed look at the extent to which the wealthiest in the United States are able to live lives of extraordinary privilege and luxury while simultaneously paying low rates of income tax or no income tax at all.

Among the findings is that Amazon founder Jeff Bezos, the wealthiest person in the world, according to Forbes magazine, paid no federal income taxes in 2007 and 2011, and that other billionaires with household names — Warren Buffett, Mark Zuckerberg, George Soros, Michael Bloomberg, Carl Icahn and others — managed to pay very small amounts of taxes to the federal government, or none at all, even in years when their wealth grew by billions of dollars.

Income vs. wealth

It is important to note the difference between “income” and “wealth” for purposes of the tax code. When an individual files a tax return, it is income that the government is measuring — the proceeds of wages, interest and business activities. Wealth, by contrast, encompasses not just money saved from income from labor or interest, but capital holdings — stocks, bonds, real estate — that may appreciate significantly in value but do not produce income until they are sold.

According to the report, the data show that the 25 richest people in the U.S. saw their wealth increase by a combined $401 billion between 2014 and 2018. But over that period, they paid only $13.6 billion in taxes, or about 3.4% of that increase. That’s because they were taxed only on money that counted as income, which in most cases represented only a tiny percentage of the increase in their total net worth over that period.

By contrast, the median U.S. household pays about 14% of annual income in taxes every year. According to ProPublica’s research, over the same five-year period, the wealth of the average American middle-class family increased by about $65,000, largely because of rising home prices. But that increase in wealth was very nearly balanced by the families’ $62,000 in tax payments across those years.

Monetizing unrealized gains

The ProPublica data illustrate how the very wealthy are able to minimize income, even as they continue to spend lavishly.

In brief, the strategy is to borrow money using their wealth as collateral. Oracle founder Larry Ellison, for example, has a $10 billion credit line collateralized by the same amount of Oracle stock in his possession. Because the money drawn from that credit line is considered a loan, not income, Ellison pays no tax on it.

In theory — and probably in practice, experts say — Ellison and others can simply continue rolling over their debt throughout their lifetimes, absorbing the interest costs from the loans but never selling the underlying assets.

Shocking, but not so shocking

The information uncovered by ProPublica was shocking insofar as individuals’ tax data are very closely held by the Treasury Department and are virtually never released publicly. However, the degree to which the very wealthy are able to avoid paying taxes and the methods they use to do so were not particularly surprising to those who study the tax code.

“Tax scholars thought that this was the way it worked — that they have large assets, and they borrow because the incentives to do so are gigantic,” said Zachary D. Liscow, an associate professor at Yale Law School. “We already knew that. It’s public information when they sell [their shares], and they just haven’t sold that much. Yet they live these lavish lifestyles, which suggests that they are borrowing.”

“I think it’s a big wake-up call,” said Steve Wamhoff, director of federal tax policy for the Institute on Taxation and Economic Policy in Washington.

“It tells us things that tax experts have already known for a long time. But it’s the amount of detail, the specific names, that we don’t normally see,” Wamhoff said. “Even though we know really wealthy people have all kinds of ways to avoid taxes, there’s something about seeing actual names and actual numbers that brings that into sharper focus, and makes people think about what a problem that is, and what we can do to fix it.”

Reason not to sell

There are very obvious reasons why the owners of large paper fortunes prefer not to realize their gains by selling their holdings. The appreciation of the stock would be subject to taxes, immediately wiping out a substantial amount of their wealth.

However, if a wealthy individual holds on to stocks until death, the person’s heirs are able to inherit the holdings at their present value — a practice known as a “step-up-in-basis” — that essentially erases any tax liability that the appreciated shares had come to represent for the deceased.

In this scenario, the heirs can then sell some of the shares with little or no paper gain, use the proceeds to pay off the estate’s outstanding loans and whatever estate taxes are due, and start the whole process over again.

Policy implications

The wealthiest Americans are sitting on $2.7 trillion in unrealized capital gains, according to Emmanuel Saez and Gabriel Zucman, economists at the University of California-Berkeley.

If there are $2.7 trillion in unrealized capital gains that could somehow be subject to income tax — particularly at the 39.6% marginal rate that President Joe Biden’s administration supports — that would translate into more than $1 trillion in revenue for the federal government.

“That is a large share of the federal budget,” Liscow said. “The scope for what could be funded, or the taxes that could be reduced to middle-class families, is gigantic.”

Tax proposals

Exactly how to get at that money, though, is unclear. The kind of wealth tax that many on the left are interested in implementing has proven hopelessly complicated to administer in other advanced economies, like France.

Another option — taxing the wealthy on the money they take in via loans against their holdings — would require substantial revision to the tax code.

What advocates are most hopeful about is that the ProPublica revelations will add momentum to a push to do away with the stepped-up-basis enjoyed by the heirs of the ultrawealthy. The Biden administration has proposed just such a move alongside its budget request.

“So, at least all of that would be taxed, eventually, under the Biden proposal,” said Wamhoff, “which is the very minimum that we can do to crack down on this.”

Pessimistic note

However, Liscow said he was doubtful that the revelations would spur any other major reforms in tax policy.

In May, he and Edward G. Fox, an assistant professor at the University of Michigan Law School, released a draft of a paper documenting a survey of approximately 5,000 people, done to gauge support for how the United States taxes returns on investment. The results found broad support for a system that taxes gains only after they are realized.

Even when presented with a scenario mirroring the ProPublica report, in which a wealthy individual borrows against large unrealized gains, a majority of respondents did not support the idea of levying a tax on the borrowed funds.

While he said he personally thought the very wealthy should pay more, Liscow said, “Am I hopeful that this will substantially move the needle? No, I’m not.”

Source: Voice of America

Aero-Engine industry professionals to gather in Dallas June 30-July 1 for Aviation Week Network’s Aero-Engines Americas 2021

NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) — Aero-engine professionals will converge on June 30-July 1 at the Fairmont Dallas for Aviation Week Network’s Aero-Engines Americas 2021 conference to capitalize on the engine MRO market’s recovery and anticipated growth. The hybrid event will be held in-person with the option for attendees to participate virtually.

The two-day conference is exclusively dedicated to the trends and issues related to the America’s engine MRO community, gathering attendees from nearly 200 companies including airlines (Alaska Airlines, All Nippon Airways, Allegiant Airlines, Amazon Air, American Airlines, Asia Pacific Airlines, Delta Airlines, Southwest Airlines, United Airlines), MROs, OEMs, lessors and suppliers.

The event includes two days of industry expert speakers, an exhibitor showcase, two evening cocktail networking sessions, lunches and coffee breaks. For a full agenda and list of speakers see here and to register see here.

“Aero-Engines Americas’ role as the premier conference for the region’s engine community is more important than ever, providing a forum to reconnect safely and plan the recovery,” said Lydia Janow, Managing Director of Events for Aviation Week Network. “Attendees have the opportunity to access the knowledge they need to help rebuild and restore the engine industry. Our agenda has been created from critical research we have conducted with past speakers, attendees, and other industry experts.”

Exclusively for Aero-Engines Americas attendees, BP Aero will host a shop tour of its facilities located near the DFW airport on the afternoon of Thursday, July 1. BP Aero is a full service aviation solutions provider specializing in engine teardown, engine part overhaul, accessory overhaul, lease returns and engine hospital shop repairs.

Aero-Engines Americas 2021 Host Sponsor is BP Aero with Engine Lease FinanceLockheed Martin Engine SolutionsRamco, and StandardAero serving as event sponsors.

ABOUT AVIATION WEEK NETWORK 
Aviation Week Network is the largest multimedia information and services provider for the global aviation, aerospace, and defense industries, serving 1.7 million professionals around the world. Industry professionals rely on Aviation Week Network to help them understand the market, make decisions, predict trends, and connect with people and business opportunities. Customers include the world’s leading aerospace manufacturers and suppliers, airlines, airports, business aviation operators, militaries, governments and other organizations that serve this worldwide marketplace. Aviation Week Network’s portfolio delivers award-winning journalism, data, intelligence and analytical resources, world-class tradeshows and conferences, and results-driven marketing services and advertising is helping our customers succeed. Aviation Week Network is part of Informa Markets, a division of Informa PLC.

ABOUT INFORMA MARKETS
Informa Markets creates platforms for industries and specialist markets to trade, innovate and grow. Our portfolio is comprised of more than 550 international B2B events and brands in markets including Healthcare & Pharmaceuticals, Infrastructure, Construction & Real Estate, Fashion & Apparel, Hospitality, Food & Beverage, and Health & Nutrition, among others. We provide customers and partners around the globe with opportunities to engage, experience and do business through face-to-face exhibitions, specialist digital content and actionable data solutions. As the world’s leading exhibitions organiser, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year. For more information, please visit www.informamarkets.com.

Elizabeth Kelley Grace
Elizabeth@thebuzzagency.net
561.702.7471

Ocean Biomedical, Inc. Files Registration Statement For Proposed Initial Public Offering

PROVIDENCE, R.I., June 10, 2021 (GLOBE NEWSWIRE) — Ocean Biomedical, Inc. (“Ocean”) today announced that it has publicly filed a Registration Statement on Form S-1 (the “Registration Statement”) with the Securities and Exchange Commission (the “SEC”) relating to a proposed initial public offering of shares of its common stock. Ocean intends to list its common stock on the Nasdaq Global Market under the symbol “OCEA.” The size of the proposed offering and price range for the proposed offering have not yet been determined.

It is expected that the net proceeds from Ocean’s initial public offering will be used to fund the clinical development and preclinical development of Ocean’s assets, and for business development activities, working capital and other general corporate purposes.

Berenberg and Oppenheimer & Co. are acting as joint bookrunning managers for the offering. LifeSci Capital, Ladenburg Thalmann, Brookline Capital Markets and Roth Capital Partners are acting as co-managers for the offering.

The proposed offering will be made only by means of a prospectus. Copies of the preliminary prospectus relating to the offering may be obtained, when available, from: Berenberg Capital Markets LLC, Attention: Investment Banking, 1251 Avenue of the Americas, 53rd Floor, New York, New York 10020, or by telephone at +1 (646) 949-9000, or by e-mail at prospectusrequests@berenberg-us.com, or Oppenheimer & Co. Inc., Attn: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY 10004, or by calling (212) 667-8055, or by emailing EquityProspectus@opco.com.

The Registration Statement has been filed with the SEC but has not yet become effective. The securities may not be sold nor may offers to buy be accepted prior to the time the Registration Statement becomes effective. The initial public offering is expected to take place after the SEC completes its review process, subject to market and other conditions.

This press release is being made pursuant to, and in accordance with, Rule 134 under the Securities Act of 1933, as amended (the “Securities Act”), and shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act.

Forward-Looking Statements

This release may contain certain forward-looking statements relating to us and our business which involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words “proposed” and “expect” or similar expressions are intended to identify forward-looking statements. Such forward-looking statements include, but are not limited to, statements relating to the proposed initial public offering, including the size of such offering, the plan to list on the Nasdaq Global Market, the expected timing of such initial public offering and the expected use of proceeds from such initial public offering. The forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, many of which are beyond our control, are difficult to predict and could cause actual results to differ materially from those expressed or forecast in the forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to uncertainties related to market conditions and the SEC’s review process, and other factors relating to our business described in the section entitled “Risk Factors” in the Registration Statement. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date of this release. The factors described therein are not necessarily all of the important factors that could cause actual results or developments to differ materially from those expressed in any of our forward-looking statements. Other unknown or unpredictable factors also could affect our forward-looking statements. Consequently, our actual performance could be materially different from the results described or anticipated by our forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by the federal securities laws, we undertake no obligation to update any forward-looking statements.

SOURCE Ocean Biomedical, Inc.

Kevin Kertscher
Communications Director
Ocean Biomedical
kkertscher@oceanbiomedical.com 
(401) 642-6322

Bright Peak Therapeutics Announces $107 Million Series B Financing and Expanded Board of Directors

–Proceeds to advance company’s pipeline of next-generation cytokine immunotherapies–
–Laura Shawver, Christine Siu join as independent directors–

BASEL, Switzerland and SAN DIEGO, Calif., June 10, 2021 (GLOBE NEWSWIRE) — Bright Peak Therapeutics, a biotechnology company developing next-generation cytokine immunotherapies to treat cancer and autoimmune disease, today announced that it raised $107 million in a Series B financing. The round was led by RA Capital, with participation by founding investor Versant Ventures and new investors Fidelity Management & Research Company, Invus, Qatar Investment Authority, funds and accounts managed by BlackRock, Alexandria Venture Investments and an undisclosed leading healthcare investment fund.

Bright Peak uses a novel technology to chemically synthesize therapeutic cytokines by ligating together customized peptide segments. This proprietary technology provides unique flexibility to both tune and enhance cytokine biology through affinity modification and orthogonal, site-specific conjugation. The company’s platform also allows for the conjugation of its enhanced cytokines as payloads to certain antibodies, creating novel and proprietary “Bright Peak Immunocytokines.” These Immunocytokines will allow tissue- and cell-specific targeting of the cytokine payload with the added potential for synergistic efficacy through potency-enhancing avidity effects.

“The investment from this accomplished crossover syndicate underscores the enthusiasm for our platform and re-affirms our commitment to transform the therapeutic utility of cytokines to treat people with cancer and autoimmune diseases,” said Fredrik Wiklund, president and CEO of Bright Peak. “This capital will allow us to expand our Immunocytokine platform and advance our deep pipeline of programs across IL-2, IL-18 and IL-7.”

Also today, Bright Peak announced key additions to its board of directors with the appointments of independent directors Laura Shawver, Ph.D., and Christine Siu. Dr. Shawver, currently CEO of Silverback Therapeutics, is an industry veteran with an extensive scientific, translational and clinical background as well as a broad range of strategic expertise. Most recently, she was president and CEO of Synthorx, a developer of engineered cytokines for cancer and autoimmune disorders that was acquired by Sanofi in 2020 for $2.5 billion. She received her Ph.D. in pharmacology from the University of Iowa.

Ms. Siu is the chief operating officer in-residence at BridgeBio Pharma Inc., and former CFO at Eidos Therapeutics Inc., a BridgeBio subsidiary, where she transformed Eidos from a preclinical biotech start-up company to a late-stage clinical public company. Prior to that, she was the CBO at The Bluefield Project to Cure Frontotemporal Dementia, where she built a therapeutic pipeline and executed seven collaborations with the pharmaceutical industry. Earlier, she was senior director, corporate development at Global Blood Therapeutics, Inc. (GBT), and before that, a venture principal at Third Rock Ventures. Previously, Ms. Siu invested in life science companies in venture capital and private equity and held roles of increasing responsibility at Warburg Pincus LLC and Thomas, McNerney & Partners, LLC and began her career in healthcare banking at Bear, Stearns & Co. Inc. Ms. Siu holds an MBA from Harvard Business School and a B.S. with distinction in cellular molecular biology and economics from the University of Michigan.

On the Bright Peak board, Dr. Shawver and Ms. Siu join RA Capital’s Josh Resnick, M.D., and Michael Rosenzweig DVM, Ph.D., who joined in connection with the Series B financing, as well as existing board members Alex Mayweg, Ph.D., and Tom Woiwode, Ph.D., of Versant Ventures.

“We are pleased to lead a financing that will enable Bright Peak to broadly invest in its platform technologies, development programs, people, and, ultimately, towards delivering a pioneering new category of cytokine immunotherapies to patients in need,” said Dr. Resnick.

“We warmly welcome Laura, Christine, Josh, and Michael to our Board of Directors. Their deep domain expertise and business acumen will serve as a tremendous resource to the Company,” said Dr. Mayweg.

About Bright Peak

Bright Peak is a privately held biotechnology company based in San Diego, CA and Basel, Switzerland developing innovative cytokine therapeutics that are uniquely engineered to precisely tune and control desired biological properties. Using its proprietary Enhanced Design and Combine (EDC) chemistry platform, Bright Peak is developing an emerging portfolio of novel designer immunotherapies for the treatment of cancer and autoimmune diseases. Bright Peak is also pioneering a new category of “Bright Peak Immunocytokines” that simultaneously leverages the precision of antibody targeting with cytokine-mediated selective immune modulation in the desired microenvironment.

Contact:
info@brightpeaktx.com